The number of product recalls in the UK jumped by 8 per cent in the
last year, with the problem compounded by the trend towards
outsourcing to developing countries such as those in Asia, says law
firm Reynolds Porter Chamberlain (RPC).
Bridge Pharmaceuticals has just launched a new training scheme
between its facilities in the US and China to enable its employees
to cross train in both labs - a potential competitive advantage for
a contract research organisation...
A number of executives and technical staff at small to medium size
pharmaceutical firms are unaware of how to use their resources
effectively to comply with new EMEA guidelines, designed to
minimise the environmental impact of compounds,...
Pharmaceutical companies are beginning to catch up with other
industry sectors that take an increasingly realistic view of what
they consider a core competency and outsourcing what is left -
Outsourcing-Pharma takes a snapshot of...
Two trade associations of the world's two largest pharma economies
- Europe and the US - took the unusual step of banding together at
the CPhI in Paris to condemn their regulatory authorities for poor
regulation of foreign active...
A draft guidance has been published by the Food and Drug
Administration (FDA) to help the industry wade through the
potential minefield of conducting clinical research on patients
without informed consent, in cases of emergencies.
Dalton Pharma Services has introduced a range of new medicinal
chemistry services that are available to companies involved in drug
discovery that wish to utilise additional scientific and managerial
expertise as well as specialised...
Researchers have published a new article launching a scathing
attack on the growing incidence of healthcare professionals being
paid exuberant 'finder's fees' whenever they recruit a patient onto
a clinical trial.
The Food and Drug Administration (FDA) will beef up its process for
disclosing the conflicts of interest of its advisory experts in a
bid to restore its reputation after a survey suggests its
scientists may be too closely tied with...
The Food and Drug Administration (FDA) has been left red-faced
after a survey recently released by the Union of Concerned
Scientists (UCS), found a "disturbing level of interference in the
Outourcing-Pharma focus on: FDA clinical trial initiatives
Outsourcing-Pharma.com sheds some light on how pharma companies can
make sure they are choosing a contract research organisations (CRO)
that will stick to the rules of ethics when running clinical trials
in poorly-regulated countries...
Outsourcing-Pharma focus: cutting the cost of clinical trials
After recent allegations in the media that poor and illiterate
patients in India are being used, often unknowingly, as human
guinea pigs to test new drugs for the pharma giants of the West,
Outsourcing-Pharma takes a look at how cutting...
The US Food & Drug Administration's (FDA) drive to clear the
mounting backlog of post-marketing (Phase IV) drug trials signals
good news for the clinical research organisations (CROs) who are
poised to benefit.
Outsourcing-Pharma focus on: Phase IIIB-IV research
The US Food & Drug Administration (FDA) is investigating ways
of boosting the completion rate of new drug post marketing
commitment studies in the wake of ongoing controversy over the
agency's lack of enforcement. The answer,...
Asia and India are continuing to attract a wave of foreign
outsourcing contracts in the pharma industry, as companies are
lured by productivity-and cost savings. However, these countries
are not yet reaching their potential, as fears...